Integra LifeSciences Holdings Corporation (IART), a medical technology company, on Tuesday reported financial results for the first quarter ending March 31, 2026, reflecting a narrow net loss. In addition, the firm provided second-quarter revenue guidance and raised its full-year 2026 adjusted per-share earnings guidance.
Integra develops, manufactures, and sells products used in neurosurgery, wound care, and surgical reconstruction.
For the first quarter of 2026, the firm's net loss narrowed to $4.62 million, or $0.06 per diluted share, compared to $25.29 million, or $0.33 per share, in the prior year.
Adjusted net income increased to $41.56 million, or $0.54 per diluted share, compared to $31.65 million, or $0.41 per diluted share, in the prior year.
Revenue for the first quarter increased 2.4% to $391.92 million from $382.65 million in the prior year.
Looking ahead to the second quarter of 2026, the firm expects revenues in the range of $410 million to $425 million and adjusted per-share earnings in the range of $0.44 to $0.52.
For the full year 2026, the company is reiterating its revenue guidance range of $1.662 billion to $1.702 billion.
In addition, the firm updated its expected adjusted EPS to a range of $2.40 to $2.50 per share, reflecting the first-quarter benefits from the IEEPA tariffs, up from the earlier range of $2.30 to $2.40.
IART has traded between $8.70 and $16.49 over the last year. The stock closed Monday's trade at $10.65, down 2.74%.
In the premarket, IART is up 10.33% at $11.75.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.